← Back to Screener
Insmed, Inc. (INSM)
Price$142.82
Favorite Metrics
Price vs S&P 500 (26W)-19.74%
Price vs S&P 500 (4W)-3.26%
Market Capitalization$31.01B
All Metrics
Book Value / Share (Quarterly)$3.45
P/TBV (Annual)57.88x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)35.20%
Cash Flow / Share (Quarterly)$-4.52
Price vs S&P 500 (YTD)-21.12%
Gross Margin (TTM)79.73%
Net Profit Margin (TTM)-210.54%
EPS (TTM)$-6.40
10-Day Avg Trading Volume1.98M
EPS Excl Extra (TTM)$-6.40
Revenue Growth (5Y)29.83%
EPS (Annual)$-6.42
ROI (Annual)-87.04%
Gross Margin (Annual)79.73%
Net Profit Margin (5Y Avg)-226.84%
Cash / Share (Quarterly)$6.67
Revenue Growth QoQ (YoY)152.62%
ROA (Last FY)-56.38%
Revenue Growth TTM (YoY)66.73%
EBITD / Share (TTM)$-6.25
ROE (5Y Avg)-250.53%
Operating Margin (TTM)-205.59%
Cash Flow / Share (Annual)$-4.52
P/B Ratio41.97x
P/B Ratio (Quarterly)50.23x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)51.50x
Net Interest Coverage (TTM)-53.96x
ROA (TTM)-57.33%
EV / EBITDA (TTM)261.31x
EPS Incl Extra (Annual)$-6.42
Current Ratio (Annual)3.83x
Quick Ratio (Quarterly)3.35x
3-Month Avg Trading Volume2.78M
52-Week Price Return105.81%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$2.99
P/S Ratio (Annual)51.14x
Asset Turnover (Annual)0.27x
52-Week High$212.75
Operating Margin (5Y Avg)-214.86%
EPS Excl Extra (Annual)$-6.42
CapEx CAGR (5Y)36.70%
Tangible BV CAGR (5Y)25.26%
26-Week Price Return-11.00%
Quick Ratio (Annual)3.35x
13-Week Price Return-11.61%
Total Debt / Equity (Annual)0.98x
Current Ratio (Quarterly)3.83x
Enterprise Value$31,232.165
Revenue / Share Growth (5Y)12.59%
Asset Turnover (TTM)0.27x
Book Value / Share Growth (5Y)3.40%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)1.07x
Pretax Margin (Annual)-209.71%
Cash / Share (Annual)$6.67
3-Month Return Std Dev44.67%
Gross Margin (5Y Avg)77.75%
Net Income / Employee (TTM)$-1
ROE (Last FY)-172.78%
Net Interest Coverage (Annual)-53.96x
EPS Basic Excl Extra (Annual)$-6.42
Receivables Turnover (TTM)6.29x
Total Debt / Equity (Quarterly)0.98x
EPS Incl Extra (TTM)$-6.40
Receivables Turnover (Annual)6.29x
ROI (TTM)-78.43%
P/S Ratio (TTM)51.14x
Pretax Margin (5Y Avg)-226.38%
Revenue / Share (Annual)$3.05
Tangible BV / Share (Annual)$2.99
Price vs S&P 500 (52W)70.72%
Year-to-Date Return-16.98%
5-Day Price Return-4.41%
EPS Normalized (Annual)$-6.42
ROA (5Y Avg)-44.38%
Net Profit Margin (Annual)-210.54%
Month-to-Date Return-11.64%
Cash Flow / Share (TTM)$-5.17
EBITD / Share (Annual)$-6.24
Operating Margin (Annual)-205.59%
LT Debt / Equity (Annual)0.95x
ROI (5Y Avg)-54.58%
LT Debt / Equity (Quarterly)0.95x
EPS Basic Excl Extra (TTM)$-6.40
P/TBV (Quarterly)57.88x
P/B Ratio (Annual)50.23x
Inventory Turnover (TTM)1.07x
Pretax Margin (TTM)-209.71%
Book Value / Share (Annual)$3.45
Price vs S&P 500 (13W)-14.48%
Beta0.97x
Revenue / Share (TTM)$2.84
ROE (TTM)-168.36%
52-Week Low$63.81
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.28
4.26
4.27
4.31
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
INSMInsmed, Inc. | 51.14x | 66.73% | 79.73% | — | $142.82 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Insmed is a biopharmaceutical company with two commercial respiratory products, Arikayce and Brinsupri, which generate revenue primarily from the United States. Its clinical pipeline spans respiratory, immunology, inflammation, and rare neurological disorders, including programs TPIP, INS1148, brensocatib, and INS1201. Pre-clinical research encompasses gene therapy, AI-driven protein engineering, and RNA end-joining technologies.